175 related articles for article (PubMed ID: 23758044)
21. BCR/ABL oncogene directly controls MHC class I chain-related molecule A expression in chronic myelogenous leukemia.
Boissel N; Rea D; Tieng V; Dulphy N; Brun M; Cayuela JM; Rousselot P; Tamouza R; Le Bouteiller P; Mahon FX; Steinle A; Charron D; Dombret H; Toubert A
J Immunol; 2006 Apr; 176(8):5108-16. PubMed ID: 16585609
[TBL] [Abstract][Full Text] [Related]
22. The decreased susceptibility of Bcr/Abl targets to NK cell-mediated lysis in response to imatinib mesylate involves modulation of NKG2D ligands, GM1 expression, and synapse formation.
Cebo C; Da Rocha S; Wittnebel S; Turhan AG; Abdelali J; Caillat-Zucman S; Bourhis JH; Chouaib S; Caignard A
J Immunol; 2006 Jan; 176(2):864-72. PubMed ID: 16393970
[TBL] [Abstract][Full Text] [Related]
23. Status of leptin in MBCR-ABL p210 positive chronic myeloid leukemia patients before and after imatinib therapy: a conflicting scenario.
Bansal P; Ghalaut VS; Sharma TK; Ghalaut PS; Dokwal S; Ghalaut R; Kulshrestha M; Dahiya K
Clin Lab; 2014; 60(11):1845-52. PubMed ID: 25648025
[TBL] [Abstract][Full Text] [Related]
24. Clinical significance of BCR-ABL fusion gene subtypes in chronic myelogenous and acute lymphoblastic leukemias.
Ye YX; Zhou J; Zhou YH; Zhou Y; Song XB; Wang J; Lin L; Ying BW; Lu XJ
Asian Pac J Cancer Prev; 2014; 15(22):9961-6. PubMed ID: 25520136
[TBL] [Abstract][Full Text] [Related]
25. Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline.
Branford S; Yeung DT; Parker WT; Roberts ND; Purins L; Braley JA; Altamura HK; Yeoman AL; Georgievski J; Jamison BA; Phillis S; Donaldson Z; Leong M; Fletcher L; Seymour JF; Grigg AP; Ross DM; Hughes TP
Blood; 2014 Jul; 124(4):511-8. PubMed ID: 24859364
[TBL] [Abstract][Full Text] [Related]
26. [Treatment-free molecular remission achieved by combination therapy with imatinib and IFNα in CML with BIM deletion polymorphism relapsed after stop imatinib].
Katagiri S; Tauchi T; Umezu T; Saito Y; Suguro T; Asano M; Yoshizawa S; Kitahara T; Akahane D; Tanaka Y; Fujimoto H; Okabe S; Gotoh M; Ito Y; Ohyashiki JH; Ohyashiki K
Rinsho Ketsueki; 2015 Feb; 56(2):216-9. PubMed ID: 25765803
[TBL] [Abstract][Full Text] [Related]
27. [A retrospective study of chronic myelocytic leukemia treatment with imatinib and interferon-α].
Wu SH; Zheng CP; Xu J
Zhonghua Xue Ye Xue Za Zhi; 2012 Apr; 33(4):311-5. PubMed ID: 22781725
[TBL] [Abstract][Full Text] [Related]
28. Monitoring twenty-six chronic myeloid leukemia patients by BCR-ABL mRNA level in bone marrow:a single hospital experience.
Sakamoto Y; Mariya Y; Oshikiri T; Sasaki S; Segawa M; Teshiromori R; Ogura K; Akagi T; Kaimori M; Kubo K
Acta Med Okayama; 2011 Oct; 65(5):335-42. PubMed ID: 22037271
[TBL] [Abstract][Full Text] [Related]
29. Imatinib (ST1571) provides only limited selectivity for CML cells and treatment might be complicated by silent BCR-ABL genes.
Jiang G; Yang F; Li M; Weissbecker K; Price S; Kim KC; La Russa VF; Safah H; Ehrlich M
Cancer Biol Ther; 2003; 2(1):103-8. PubMed ID: 12673129
[TBL] [Abstract][Full Text] [Related]
30. Tetrandrine citrate eliminates imatinib-resistant chronic myeloid leukemia cells in vitro and in vivo by inhibiting Bcr-Abl/β-catenin axis.
Xu XH; Gan YC; Xu GB; Chen T; Zhou H; Tang JF; Gu Y; Xu F; Xie YY; Zhao XY; Xu RZ
J Zhejiang Univ Sci B; 2012 Nov; 13(11):867-74. PubMed ID: 23125079
[TBL] [Abstract][Full Text] [Related]
31. Is it possible to discontinue imatinib mesylate therapy in Chronic Myeloid Leukemia patients with undetectable BCR/ABL? A case report and a review of the literature.
Guastafierro S; Falcone U; Celentano M; Coppola M; Ferrara MG; Sica A
Leuk Res; 2009 Aug; 33(8):1079-81. PubMed ID: 19167064
[TBL] [Abstract][Full Text] [Related]
32. Erosion of the chronic myeloid leukaemia stem cell pool by PPARγ agonists.
Prost S; Relouzat F; Spentchian M; Ouzegdouh Y; Saliba J; Massonnet G; Beressi JP; Verhoeyen E; Raggueneau V; Maneglier B; Castaigne S; Chomienne C; Chrétien S; Rousselot P; Leboulch P
Nature; 2015 Sep; 525(7569):380-3. PubMed ID: 26331539
[TBL] [Abstract][Full Text] [Related]
33. Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation.
Merante S; Orlandi E; Bernasconi P; Calatroni S; Boni M; Lazzarino M
Haematologica; 2005 Jul; 90(7):979-81. PubMed ID: 15996937
[TBL] [Abstract][Full Text] [Related]
34. Association of genotypes and haplotypes of multi-drug transporter genes ABCB1 and ABCG2 with clinical response to imatinib mesylate in chronic myeloid leukemia patients.
Au A; Aziz Baba A; Goh AS; Wahid Fadilah SA; Teh A; Rosline H; Ankathil R
Biomed Pharmacother; 2014 Apr; 68(3):343-9. PubMed ID: 24581936
[TBL] [Abstract][Full Text] [Related]
35. [Imatinib mesylate for chronic myeloid leukemia: in patients with initial treatment versus those with Recombinant Human IFN-α2b treatment failure].
Jiang JH; Xu WL; Qian WB
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2015 Mar; 44(2):179-83. PubMed ID: 26038137
[TBL] [Abstract][Full Text] [Related]
36. Previous best responses can be re-achieved by resumption after imatinib discontinuation in patients with chronic myeloid leukemia: implication for intermittent imatinib therapy.
Goh HG; Kim YJ; Kim DW; Kim HJ; Kim SH; Jang SE; Lee J; Kim D; Kim WS; Park SH; Kweon IY
Leuk Lymphoma; 2009 Jun; 50(6):944-51. PubMed ID: 19479613
[TBL] [Abstract][Full Text] [Related]
37. Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV.
Kalmanti L; Saussele S; Lauseker M; Müller MC; Dietz CT; Heinrich L; Hanfstein B; Proetel U; Fabarius A; Krause SW; Rinaldetti S; Dengler J; Falge C; Oppliger-Leibundgut E; Burchert A; Neubauer A; Kanz L; Stegelmann F; Pfreundschuh M; Spiekermann K; Scheid C; Pfirrmann M; Hochhaus A; Hasford J; Hehlmann R
Leukemia; 2015 May; 29(5):1123-32. PubMed ID: 25676422
[TBL] [Abstract][Full Text] [Related]
38. No significance of derivative chromosome 9 deletion on the clearance kinetics of BCR/ABL fusion transcripts, cytogenetic or molecular response, loss of response, or treatment failure to imatinib mesylate therapy for chronic myeloid leukemia.
Kim DH; Popradi G; Sriharsha L; Kamel-Reid S; Chang H; Messner HA; Lipton JH
Cancer; 2008 Aug; 113(4):772-81. PubMed ID: 18543309
[TBL] [Abstract][Full Text] [Related]
39. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.
Paschka P; Müller MC; Merx K; Kreil S; Schoch C; Lahaye T; Weisser A; Petzold A; König H; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Leukemia; 2003 Sep; 17(9):1687-94. PubMed ID: 12970765
[TBL] [Abstract][Full Text] [Related]
40. PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia.
Wolff NC; Veach DR; Tong WP; Bornmann WG; Clarkson B; Ilaria RL
Blood; 2005 May; 105(10):3995-4003. PubMed ID: 15657179
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
